Circle Pharma Congratulates Dr. William G. Kaelin, Jr., MD on Award of Nobel Prize
Circle Pharma congratulates 2019 Nobel laureate Dr. Bill Kaelin. Dr. Kaelin advises Circle on its work to develop cyclin inhibitors for cancer., [...]
Circle Pharma Announces Publication in Journal of Medicinal Chemistry of Results from Collaboration with Pfizer Inc.
Results from its collaborative work with Pfizer to develop a potent and orally bioavailable macrocycle modulator have been published [...]
Circle Pharma Announces Appointment of David Spellmeyer, PhD, as Chief Scientific Officer
David Spellmeyer, PhD, has been appointed as Circle Pharma's chief scientific officer [...]
Circle Pharma announces expansion of Series A financing and appointment of James C. Lu to its board
An expansion of Series A financing has been completed, with new investors W.I. Harper Group, [...]
Circle Pharma announces Series A financing and appoints Walter H. Moos, Ph.D., to its board
Series A financing round has been announced in which over $4.5M of shares have been issued [...]
Circle Pharma enters into an agreement with Pfizer to build screening library of macrocyclic peptides
Designing and creating a physical screening library of novel macrocyclicpeptides [...]
Circle Pharma Announces Appointment of Co-Founder Prof. Matthew Jacobson to Department Chair
Co-founder Prof. M. Jacobson has been appointed Chair of the UCSF Department of Pharm. Chemistry [...]
Circle Pharma Announces Receipt of Additional Seed Investment, and Relocation to New Laboratory Facility
The seed funding round has been extended with an investment from ShangPharma Investment Group [...]
Circle Pharma Announces Receipt of Seed Funding and Initiation of Two Collaborations
Circle Pharma has received seed funding from Pfizer Inc. and QB3’s seed-stage venture fund, Mission Bay Capital, LLC, and has initiated two collaborations with Pfizer [...]